Aurealis Pharma

Embracing science. Enhancing lives.

Aurealis Pharma is a emerging biopharmaceutical company
with a disruptive technology enabling combination immunotherapy with superior efficacy.
Read more

Aurealis Pharma is developing an innovative gene therapy platform (AUP) focusing on immune microenvironment modulation for durable systemic anti-cancer response. This is achieved by enabling combination immunotherapy in a single drug product.

AUP is based on safe food-grade lactic acid bacteria delivering multiple therapeutic proteins, in a temporally coordinated fashion, to activate and modulate the innate and adaptive immune system as well as directly killing of tumor cells and inhibition of angiogenesis.

Aurealis Pharma’s unique therapeutic platform facilitates a novel class of combination immunotherapy embedded in a single product that is efficient, scalable and cost-effective.

Efficient. Our product produces and delivers multiple therapeutic proteins at the same time with continuous release avoiding frequent and high peak dosing. Moreover, two sets of therapeutic proteins can be expressed in a phased fashion with a single administration. Additionally, as our drug product is a simple bacterial cell containing immunomodulatory genes, the regulatory and manufacturing pathways are clear and economical.

Safe. No systemic administration and toxicity, but local peritumoral delivery. Safe food-grade non-pathogenic bacteria.

Easy. Our technology is easy to use. No special teams or devices needed, and re-administration is feasible.

Affordable. Scalable manufacturing process enabling supreme low COG and significant cost advantages (biologic agent with low cost).

Efficient
Multitherapy
One product
Phased MoA
Safe
Non-pehtogenic
Non-commensal
Sensitive to antibiotsics
image_w_descs
Low cost
Scaleable
Low manufacturing costs
Low Cost-of-Goods
Easy
Ready-to-use
Local administration
No special devices

Science

Aurealis Pharma technology enables delivery of therapeutic proteins to trigger immune modulation. It is a concept for activating and modulating the innate and adaptive immune systems simultaneously, resulting in durable local and systemic anti-tumor effect. The technology is based on a Dual Plasmid expression system, resulting in sustained therapeutic protein expression within the tumor microenvironment.

The Dual Plasmid expression system allows:

  • Expression of therapeutic proteins by the bacteria to stimulate the innate immune system.
  • Expression of therapeutic proteins by the human host cell after phagocytosis to stimulate the adaptive immune system in addition to direct tumor cell killing.

In the first phase of AUP-ONCO mode of action, AUP-ONCO functions as a bioreactor (a protein factory), i.e. the bacteria cell will produce and secrete therapeutic proteins into the tumour environment. These are produced with the aim to activate the immune system towards a Th1 immune response. The immune cells which will be targeted at this step are macrophages / Dendritic cells, Natural Killer cells and CTLs.

In the second phase of AUP-ONCO’s mode of action, AUP-ONCO is recognized by the immune system and “eaten-up” (i.e. phagocytosed) by activated phagocytic immune cells. These phagocytic immune cells are comprised of macrophages, dendritic cells and neutrophils. After phagocytosis, the bacterial plasmid escapes the lysosome and is released into the cytoplasmic space of the host phagocytic cell, resulting in expression of a second set of therapeutic proteins by the host cell. Furthermore, activated dendritic cells have the capacity to present tumor antigens to and activate naïve T-cells to initiate an anti-tumor response.

Thus, Aurealis Pharma technology provides for two phases of protein expression, allowing temporally coordinated modification and stimulation of the immune system.

Company

Aurealis Pharma is a Basel, Switzerland based and New Haven, CT (US) co-located privately held biopharmaceutical company led by a senior management team with a proven track record in drug discovery, development and translational research, bringing advanced therapeutic medicinal products to the clinic.

Management team

Joseph Catino

CEO

Thomas Wirth

CSO

Patrick Schacher

CFO

Board of Directors

Colin Foster

Mr. Foster has thirty years of experience as a public and private life science company Chairman, Executive Chairman, Board Member, CEO, and entrepreneur with direct leadership experience across the R&D-commercial continuum in therapeutics. As CEO, he has led multi-billion-dollar, midsized, small, and start-up life science companies financing, building, turning around, and optimizing them organically and through transformational transactions. Previously, Mr. Foster was President & CEO of Bayer Pharmaceuticals Corporation USA, and Region Head of the North American Pharmaceuticals Group of Bayer AG. Over the course of his career, Mr. Foster has successfully led the full range of company functions including the development and launch/commercialization of a variety of life science products. Additionally, he has led and executed a breadth of transactions including M&A, product/asset sales, joint ventures & collaborations/co-promotions, and in-/out-licensing arrangements

Joe Catino

Dr. Catino is a Senior Executive with extensive experience in discovery and early clinical development of small molecules, protein therapeutics and gene therapy agents. He spent 28 years in large pharmaceutical companies rising from an entry level scientist in the oncology section of Bristol Myers, to Senior Vice President of Discovery Research, Preclinical Development and Early Clinical Development at Bayer Corporation. In the latter role, Dr. Catino was a member of the US Executive Leadership Team, the International R&D Management Team and the Global Leadership Circle. He chaired the US patent committee and licensing committee. In 2008, Dr. Catino established an independent consulting company, Oaklee Consulting LLC, from which he has served large, mid-sized and small companies in the pharmaceutical and biotechnology space over the past 12 years. In 2009 Dr. Catino teamed with Yale University faculty to launch Helix Therapeutics, a gene editing company using triplex forming oligonucleotide technology.

Iain Buchanan

Iain brings to the company considerable experience in the Pharmaceutical and Biotech industries in both executive and non-executive roles. Most recently he served as CEO of NOXXON Pharma AG in Berlin. Prior to that, Iain was CEO of Novexel SA in Paris from its creation as the anti-infective spin out from Sanofi-Aventis in 2004 until its sale in 2009. Previously, he held a variety of management roles including a senior position with Vertex Pharmaceuticals where he was responsible for business development activities and for creating the European subsidiary. In the past he also worked for both Cilag AG (a division of Johnson and Johnson) and Biogen SA in Switzerland. Iain holds a Bachelor of Science in Physiology from the University of St. Andrews, Scotland, and currently serves as a non-executive director of Synairgen Plc and a member of the advisory board of Allecra Therapeutics.

Ralf Rosenow

Educated at the law schools of the University of Zurich and the University College London, Ralf was admitted to the Zurich and Swiss bar in 1989 specializing in intellectual property right exploitation contracts in life sciences as well as license agreements. After initial years of practice in renowned law firms in Zurich and London, he co-founded the Zurich based law firm Rosenow Grob Schilling in 2001, which in a merger in 2008 became Blum&Grob Attorneys at Law Ltd, Zurich, where he headed the Life Sciences Working Group as a partner until June 2016. Mr. Rosenow is also the founder of OSICOS Ltd. and the Chairman of its Board of Directors supporting and advising numerous Swiss based start-up companies primarily in the life sciences industry. He a member of the Bar Examination Board of the Canton of Zurich and a member of relevant industry related organizations such as the Licensing Executive Society (LES) and the Swiss Healthcare Licensing Group (Swiss HLG).

Thomas Wirth

Dr. Thomas Wirth is a serial entrepreneur and founder of Aurealis Pharma. He is leading the team at Aurealis Pharma as a CSO with extensive experience in gene medicine-based therapies and translational and molecular oncology. Dr. Wirth has worked during his PhD time at the Lombardi Cancer Centre, Georgetown University, after which he worked as a Research Director at Ark Therapeutics Group PLC leading the Kuopio based R&D department. He also held a position as an Adjunct Professor at the University of Eastern Finland leading multiple research projects developing Advanced Therapeutic Medicinal Products (ATMPs). Dr. Wirth has wide-ranging experience in bringing gene therapy products to the clinic, having overall scientific and product related leadership role especially in making the regulatory and product related strategic and tactical decisions in typically unfavorable conditions, such as time constrains and limited funding.

Contact

Aurealis Pharma AG
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

Aurealis Pharma Inc.
470 James St. Suite 007
New Haven, CT 06513
USA

You can contact us via email. Our email addresses are in form firstname[at]aurealispharma.com